NCT02387216 - A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

February 1, 2015

Primary Completion Date

January 2, 2019

Study Completion Date

January 2, 2019

Conditions

Non-Small Cell Lung CancerNSCLCAdenocarcinomaHeregulin

Interventions

DRUG

MM-121

Investigational, fully human antibody targeting and inhibiting ErbB3

DRUG

Docetaxel

approved chemotherapy treatment for NSCLC

Trial Locations (35)

10016

New York

10461

The Bronx

13353

Berlin

15224

Pittsburgh

19111

Philadelphia

22031

Fairfax

26121

Oldenburg

28007

Madrid

28046

Madrid

28222

Majadahonda

29010

Málaga

33612

Tampa

37203

Nashville

37232

Nashville

47905

Lafayette

50009

Zaragoza

60488

Frankfurt

60611

Chicago

69317

Centre Léon Bérard, Lyon

80336

München

85715

Tucson

90033

Los Angeles

94010

CHI Creteil, Créteil

95403

Santa Rosa

98101

Seattle

99437

Bad Berka

02114

Boston

02215

Boston

01923

Danvers

M5G 2M9

Toronto

H-1121

Budapest

H-3529

Miskolc

H-2800

Tatabánya

08916

Badalona

08035

Barcelona